Unlearn.AI

Unlearn.AI is revolutionizing clinical trials through the innovative use of AI-powered digital twins. Their flagship offering, TwinRCTs™, enables more confident and quicker clinical trials across various therapeutic areas including neuroscience, immunology, and metabolic diseases. The company's digital twin technology creates comprehensive forecasts of patients' future health using generative models trained on extensive patient-level data from previous studies. This approach allows for shorter enrollment times in late-stage studies, more confident decision-making in early-stage trials, and increased attractiveness to study participants. Unlearn.AI's method calculates prognostic scores for each patient using their digital twins, which, when adjusted for in the analysis, increases statistical power while adhering to FDA and EMA guidelines. This innovative approach results in highly powered trials with smaller control groups, potentially accelerating the drug development process and bringing new treatments to patients faster.